Story · Medicine & Biotech
Sellas’ cancer vaccine extends survival in blood cancer trial, company says
3 outlets · first reported by The Hindu Health on · latest · 4 hours of coverage · 2 countries
The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow (The Hindu Health)
Coverage, in order
-
Sellas’ cancer vaccine extends survival in blood cancer trial, company saysThe vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow
-
‘Off-the-shelf’ cancer vaccine extends survival of leukemia patients by 9 months, finds Phase 3 trial
Patients who received vaccine had median overall survival of 24 months, compared against 14.7 months among those given best treatment. It also reduced the risk of death by 41%.
-
SELLAS Cancer Vaccine Cuts Death Hazard 41% in Phase 3 AML Trial: A Genuine Breakthrough or a Biotech Victory Lap?
SELLAS Cancer Vaccine Cuts Death Hazard 41% in Phase 3 AML Trial: A Genuine Breakthrough or a Biotech Victory Lap?
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.